FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody, which specifically binds to PCSK9. A pharmaceutical composition containing the specified antibody; a nucleic acid molecule encoding the specified antibody; a vector and a host cell containing the specified nucleic acid molecule; an immunoconjugate containing the specified antibody are also disclosed. The application of the specified antibody in production of a drug for the treatment of dyslipidemia or a drug for facilitating cellular capture of low-density lipoproteins (LDL) is disclosed.
EFFECT: invention has the capability of effective treatment of diseases related to PCSK9.
15 cl, 14 dwg, 3 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
IL-5 BINDING MOLECULE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2811518C1 |
GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
Authors
Dates
2021-09-24—Published
2016-11-24—Filed